We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Technique Enables Rapid Quantification of Vaccination-Induced Immune Response
News

Technique Enables Rapid Quantification of Vaccination-Induced Immune Response

Technique Enables Rapid Quantification of Vaccination-Induced Immune Response
News

Technique Enables Rapid Quantification of Vaccination-Induced Immune Response

Credit: Pixabay.
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Technique Enables Rapid Quantification of Vaccination-Induced Immune Response"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

A global team of researchers has developed a new strategy for fast and reliable antibody tests, which can quantify the immune response induced by vaccination and reveal the timeline and stage of pathogen infection.

Led by Professor Martin Hegner, Principal Investigator in CRANN and Trinity College Dublin’s School of Physics, the team’s one-step quantitative antibody tests are conducted using (blood) serum and are on a par with the gold-standard, enzyme-linked immunosorbent assay (ELISA) technique.


The major advantage of the newly developed nano technique with respect to ELISA tests is that it is equally sensitive and able to simultaneously detect multiple target molecules – but in a fraction of the time.


As a global multidisciplinary research consortium from Europe, Africa and the US, Professor Hegner and his co-workers focused on malaria vaccines and their generated humoral immune response for case study analysis. Malaria is a life-threatening epidemic disease with 228 million estimated annual cases occurring worldwide. It caused over 400,000 deaths last year.


The team’s findings have been published today in the interdisciplinary journal, Nanoscale, which is a high-impact, peer-reviewed journal of the Royal Society of Chemistry.


Professor Hegner said, “The current worldwide situation caused by the spread of SARS-CoV-2 cannot leave us blind towards the ongoing malaria plague that our technology directly addresses. While malaria is our published test case, we believe that this new technology will improve antibody testing in a broad range of diseases and infections.”


“The direct technique greatly simplifies the preparation protocol that in ELISA includes many washings and waiting steps, hence reducing the amount of consumables needed and thus the relative cost. It will therefore be well suited to use in emergency situations.”


“Due to the COVID-19 pandemic, it has been increasingly emphasised during such a tough year that a novel diagnostic tool must be added to our arsenal. Our technology is capable of directly quantifying immune responses with potential application across a range of diseases. We are currently investigating its applicability to COVID-19 antigen responses.”

Reference
Brunetti G, Padovani F, Pastina AD, et al. Nanotechnological immunoassay for rapid label-free analysis of candidate malaria vaccines. Nanoscale. 2021;13(4):2338-2349. doi:10.1039/D0NR08083G



This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement